Skip to main content

Algal Toxins as Guidance to Identify Phosphoproteins with Key Roles inApoptotic Cell Death

Buy Article:

$63.00 plus tax (Refund Policy)

The protein phosphatase inhibiting toxins microcystin and nodularin act rapidly to induce apoptotic cell death.Their inhibitory effect on protein phosphatases 1 and 2A can be utilized as tools to understand the phosphorylation-dependent regulatory mechanism underlying the early stage of apoptosis. The incubation of freshly isolated hepatocyteswith these toxins results in a rapid hyperphosphorylation of cellular proteins before any morphological signs of apoptosisappears [Fladmark, K. E., Brustugun, O. T., Hovland, R., Boe, R., Gjertsen, B. T., Zhivotovsky, B. and Doskeland, S. O.(1999) Cell Death Differ. 6, 1099-108]. Proteins subjected to phosphorylation in this early phase of apoptosis may playkey roles in this cellular process and become valuable targets for drug development. The ultra-rapid apoptosis-inductionby microcystin and nodularin provides a unique amount of synchronized apoptotic cells with "large" amounts of mainlyserine/threonine phosphorylated proteins. This ultra-rapid toxin-induced up-concentration of phosphorylated proteins re-duces the material needed as well as simplifies our effort in order to obtain enough phosphoproteins for mass spectromet-ric identification and characterization. We will here give an overview of our strategy for identification of low-abundancephosphoproteins involved in algal toxin-induced apoptosis and most likely also in a general apoptotic pathway.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Phosphatase inhibitor; apoptosis; massspectrometry; microcystin; nodularin; phosphopeptide enrichment; phosphorylation

Document Type: Research Article

Affiliations: Proteomic Unit, Dept. ofBiomedicine,University of Bergen. Jonas Lies vei 91, N-5009, Norway.

Publication date: 01 June 2006

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more